Rate of vision loss in neovascular age-related macular degeneration explored

Real, Juan Pablo; Granero, Gladys E.; Santis, Mariana Olga De; Juárez, Claudio P.; Palma, Santiago Daniel; Kelly, Simon P.; Luna, José D.

doi:10.1007/s00417-014-2885-y

Cited by 18 publications

(17 citation statements)

References 15 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of vectors to deliver an inhibitor of neovascularization into the subretinal space of nvAMD patients will benefit those patients, in which the RPE cells retain normal function. However, in nvAMD patients, RPE cells degenerate rapidly 20 . Regain of vision in most nvAMD patients will require not only the expression of an inhibitor of neovascularization, but more importantly a functional retinal pigment epithelium.…”

Section: Introductionmentioning

confidence: 99%

Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids

Thumann

Harmening

Prat-Souteyrand

et al. 2017

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Neovascular age-related macular degeneration (nvAMD) is characterized by choroidal blood vessels growing into the subretinal space, leading to retinal pigment epithelial (RPE) cell degeneration and vision loss. Vessel growth results from an imbalance of pro-angiogenic (e.g., vascular endothelial growth factor [VEGF]) and anti-angiogenic factors (e.g., pigment epithelium-derived factor [PEDF]). Current treatment using intravitreal injections of anti-VEGF antibodies improves vision in about 30% of patients but may be accompanied by side effects and non-compliance. To avoid the difficulties posed by frequent intravitreal injections, we have proposed the transplantation of pigment epithelial cells modified to overexpress human PEDF. Stable transgene integration and expression is ensured by the hyperactive Sleeping Beauty transposon system delivered by pFAR4 miniplasmids, which have a backbone free of antibiotic resistance markers. We demonstrated efficient expression of the PEDF gene and an optimized PEDF cDNA sequence in as few as 5 × 103 primary cells. At 3 weeks post-transfection, PEDF secretion was significantly elevated and long-term follow-up indicated a more stable secretion by cells transfected with the optimized PEDF transgene. Analysis of transgene insertion sites in human RPE cells showed an almost random genomic distribution. The results represent an important contribution toward a clinical trial aiming at a non-viral gene therapy of nvAMD.

show abstract

Section: Introductionmentioning

confidence: 99%

Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids

Thumann

Harmening

Prat-Souteyrand

et al. 2017

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…In some regions and health systems around the World, patients may experience delay in access for AMD-related care due to clinical or nonclinical circumstances. An example of such circumstances has been described by Real et al 11 in Argentina, where funding approval for ranibizumab is typically delayed for 160 days in order to verify clinical need, leading to significant visual decline. Similar delays to treatment, as a consequence of clinical verification of need have also been reported in Germany.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab

Massamba¹,

Dirani

Knoeri³

et al. 2015

Eye

View full text Add to dashboard Cite

“…As the aging population and average life expectancy increase, the incidence of AMD is growing in developing countries [1]. The efficacy and safety of the anti-VEGF medicine, ranibizumab (Lucentis), to treat wet age-related macular degeneration (wAMD) have been demonstrated in many large samples, multicenter randomized clinical trials, and substantial clinical practice [2, 3].…”

Section: Introductionmentioning

confidence: 99%

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results

Huang

Zhao

et al. 2016

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To observe the effect of intravitreal ranibizumab injection on wet age-related macular degeneration (wAMD) over 5 years in Chinese patients. Methods. Thirty-seven patients who were diagnosed with wAMD in our hospital from June 2007 to June 2014 were retrospectively reviewed. The PRN regimen and the treatment and extend regimen were applied. Best corrected visual acuity (BCVA), number of ranibizumab injections, and changes in the choroidal neovascularization (CNV) lesion over 5 years were analyzed. Results. The mean BCVA measured by the ETDRS chart at baseline was 47.4 and 5 years after the treatment it was 34.89 letters, which was significantly different (p = 0.013). Fourteen eyes (37.8%) had improved visual acuity after 5 years. The number of injections in 5 years was 11.53, and most of the injections were in the first two years. Seventeen (45.9%) cases developed fibrous lesions, and 2 (5.4%) cases had atrophic lesions after 5 years. The fibrosis/atrophy was significantly correlated with the injection numbers (Pearson, r = 0.663, and p = 0.000). Conclusion. Most of the patients can maintain visual acuity treated by ranibizumab in the first 3 years. After 5 years, some patients can still improve or maintain visual acuity. Fibrous scarring of the lesion is the main reason for a decrease in vision of wAMD patients.

show abstract

Rate of vision loss in neovascular age-related macular degeneration explored

Cited by 18 publications

References 15 publications

Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids

Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids

Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results

Contact Info

Product

Resources

About